Evaluation of the clinical efficacy and safety of the combined administration of Imidafenacin and alfa1-blocker in BPH patients with OAB.

Trial Profile

Evaluation of the clinical efficacy and safety of the combined administration of Imidafenacin and alfa1-blocker in BPH patients with OAB.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Imidafenacin (Primary) ; Alpha 1 adrenergic receptor antagonists
  • Indications Benign prostatic hyperplasia; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms FUN Study
  • Most Recent Events

    • 21 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top